Industrial interest in applying and translating epigenetic science to cancer therapy is growing at an exponential pace with many large and small companies already heavily invested in the field. Fortunately, epigenetics arrives as a science in a more collaborative era and may even have the potential to impact disease areas beyond cancer in the future. The fundamental underpinning science of the epigenome will likely be solved through partnership between academic and industrial labs.
GTC’s 3rd Cancer Epigenetics Conference, one of two parallel tracks of the 2nd Cancer Summit – Novel Approaches to Drug Discovery on November 6-8 in San Francisco, CA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.
Below are the sessions of the 3rd Cancer Epigenetics Conference:
I. Epigenetic Mechanisms in Cancer
II. Epigenetic Biomarkers and Diagnostics
III. Novel Epigenetic Targets in Early Development
IV. New Clinical Development of Epigenetic Drugs
V. Epigenetic Tools and Technologies
The conference will run parallel with the 8th Cell Based Assay & Screening Technologies as part of the 2nd Cancer Summit – Novel Approaches to Drug Discovery. Register for the summit and gain access to both conferences!